Zobrazeno 1 - 10
of 110
pro vyhledávání: '"LM Hess"'
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S162- (2023)
Objectives: Venetoclax-based therapy is a standard option for pts with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) previously treated with a covalent BTK inhibitor (cBTKi). Pirtobrutinib is a highly selective, non-covalent (reversibl
Externí odkaz:
https://doaj.org/article/7d318f13915c476ba6fcf0221626f667
Publikováno v:
Value in Health. 25:S425
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9d643ee385a7dc1307c4c95b2e55a9d
https://doi.org/10.1016/j.jval.2022.04.709
https://doi.org/10.1016/j.jval.2022.04.709
Autor:
Sanders N; Texas Children's Hospital, United States of America., Abela KM; Baylor College of Medicine, United States of America., Davenport L; Texas Children's Hospital, United States of America., Lawrence J; Texas Children's Hospital, United States of America., Gibbs K; Texas Children's Hospital, United States of America; Baylor College of Medicine, United States of America., Hess LM; Texas Children's Hospital, United States of America; Baylor College of Medicine, United States of America. Electronic address: lmhess@texaschildrens.org.
Publikováno v:
Journal of pediatric nursing [J Pediatr Nurs] 2024 Jul-Aug; Vol. 77, pp. e327-e334. Date of Electronic Publication: 2024 May 07.
Autor:
Al-Sawaf O; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Germany; Cancer Institute, University College London, United Kingdom; Francis Crick Institute, London. othman.al-sawaf@uk-koeln.de., Jen MH; Eli Lilly and Company, Bracknell., Hess LM; Eli Lilly and Company, Indianapolis, IN., Zhang J; TechDataServices, LLC, King of Prussia, PA., Goebel B; Eli Lilly and Company, Bad Homburg., Pagel JM; LOXO@Lilly, Indianapolis, IN., Abhyankar S; Eli Lilly and Company, Indianapolis, IN., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Eyre TA; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford.
Publikováno v:
Haematologica [Haematologica] 2024 Jun 01; Vol. 109 (6), pp. 1866-1873. Date of Electronic Publication: 2024 Jun 01.
Autor:
Bruno DS; University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, USA., Khanal M; Lilly Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA., Li XI; Lilly Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA., Escalon MP; Lilly Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA., Winfree KB; Lilly Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA., Hess LM; Lilly Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA, hess_lisa_m@lilly.com.
Publikováno v:
Acta haematologica [Acta Haematol] 2024 May 20, pp. 1-15. Date of Electronic Publication: 2024 May 20.
Autor:
Bruno DS; University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio., Li X; Eli Lilly and Company, Indianapolis, Indiana., Hess LM; Eli Lilly and Company, Indianapolis, Indiana.
Publikováno v:
JTO clinical and research reports [JTO Clin Res Rep] 2024 Feb 01; Vol. 5 (3), pp. 100643. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024).
Autor:
Markowitz JT; Modus Outcomes, A Division of THREAD Research, Cambridge, MA, USA., Mazerolle F; Modus Outcomes, A Division of THREAD Research, Lyon, France., Lovell T; Modus Outcomes, A Division of THREAD Research, Cambridge, MA, USA., Hess LM; Eli Lilly and Company, Indianapolis, IN, USA., Abada PB; Loxo@Lilly, Indianapolis, IN, USA., Regnault A; Modus Outcomes, A Division of THREAD Research, Lyon, France., Payakachat N; Eli Lilly and Company, Indianapolis, IN, USA. npayakachat@lilly.com.
Publikováno v:
Journal of patient-reported outcomes [J Patient Rep Outcomes] 2024 Jan 22; Vol. 8 (1), pp. 8. Date of Electronic Publication: 2024 Jan 22.
Autor:
Bhandari NR; Eli Lilly and Company, Indianapolis, Indiana., Hess LM; Eli Lilly and Company, Indianapolis, Indiana., He D; Syneos Health, Morrisville, North Carolina., Peterson P; Eli Lilly and Company, Indianapolis, Indiana.
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2023 Sep; Vol. 21 (9), pp. 934-944.e1.
Autor:
Sireci AN; Loxo@Lilly, Indianapolis, IN. Electronic address: asireci@loxooncology.com., Krein PM; Loxo@Lilly, Indianapolis, IN., Hess LM; Eli Lilly and Company, Indianapolis, IN., Khan T; Eli Lilly and Company, Indianapolis, IN., Willey J; Xcenda, Carrollton, TX., Ayars M; IntrinsiQ, Carrollton, TX., Deyoung K; Xcenda, Carrollton, TX., Bhaskar S; IntrinsiQ, Carrollton, TX., Mumuney G; IntrinsiQ, Carrollton, TX., Coutinho A; Xcenda, Carrollton, TX.
Publikováno v:
Clinical lung cancer [Clin Lung Cancer] 2023 Jul; Vol. 24 (5), pp. 429-436. Date of Electronic Publication: 2023 Mar 20.
Autor:
Eyre TA; Oxford Cancer and Hematology Centre, Oxford University NHS Foundation Trust, Oxford, UK., Hess LM; Eli Lilly and Company, Indianapolis, IN, USA., Sugihara T; Syneos Health, Inc, Morrisville, NC, USA., He D; Syneos Health, Inc, Morrisville, NC, USA., Khanal M; Eli Lilly and Company, Indianapolis, IN, USA., Pagel JM; Loxo@Lilly, Indianapolis, IN, USA., Walgren RA; Loxo@Lilly, Indianapolis, IN, USA., B Abada P; Loxo@Lilly, Indianapolis, IN, USA., Konig H; Loxo@Lilly, Indianapolis, IN, USA., Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mato A; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Publikováno v:
Leukemia & lymphoma [Leuk Lymphoma] 2023 May; Vol. 64 (5), pp. 1005-1016. Date of Electronic Publication: 2023 Mar 29.